The Federal Government and Several States Are Going After Pharmaceutical Companies That Fraudulently Market and Target Medicaid, Medicare, and Public Health Programs by Drug Company Marketing Fraud Whistleblower Lawyer, Pharmaceutical Professional Whistleblower Lawyer, Drug Company Whistleblower Medicaid Fraud Lawyer, & Drug Company Whistleblower Illegal Kickback Lawyer

The Federal Government and Several States Are Going After Pharmaceutical Companies That Fraudulently Market and Target Medicaid, Medicare, and Public Health Programs by Drug Company Marketing Fraud Whistleblower Lawyer, Pharmaceutical Professional Whistleblower Lawyer, Drug Company Whistleblower Medicaid Fraud Lawyer, & Drug Company Whistleblower Illegal Kickback Lawyer

The United States Department of Justices, Texas Attorney General, and state attorney general offices from several other states are working with Drug Company Professionals on Marketing Fraud Whistleblower Lawsuits and have begun enforcing new Medicaid fraud whistleblower recovery laws to help clean up corruption and health care fraud.  Through these new whistleblower laws and with information provided by drug company professionals through drug company whistleblower Medicaid fraud lawyers, these Medicaid fraud whistleblowers, the Department of Justices, drug company whistleblower Medicaid fraud lawyers, and state attorney generals are making large recoveries from drug companies, pharmacies, and other health care providers that have been systematically defrauding state Medicaid programs, Medicare, and other public health care programs.

USDOJ: Abbott Labs to Pay $1.5 Billion to Resolve Criminal & Civil Investigations of Off-label Promotion of Depakote

Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company’s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration (FDA), the Justice Department announced today.  The resolution – the second largest payment by a drug company – includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million.  Abbott also will be subject to court-supervised probation and reporting obligations for Abbott’s CEO and Board of Directors.

The Federal Government and Several States Including Texas Are Making Large Recoveries Through Medicaid Drug Marketing Fraud Whistleblower Lawsuits and Medicaid Drug Price Fraud Whistleblower Lawsuits by Drug Company Marketing Fraud Whistleblower Lawyer, Pharmaceutical Professional Whistleblower Lawyer, Drug Company Whistleblower Medicaid Fraud Lawyer, & Drug Company Whistleblower Illegal Kickback Lawyer

In January 2012, the State of Texas and a Medicaid drug marketing fraud  whistleblower squared off against Johnson and Johnson, Inc. and several related companies in Travis County District Court.  In the case, the State of Texas alleged that the large drug company systematically targeted the Texas Medicaid System and fraudulently misrepresented their drug, Risperdal, with false and misleading marketing information.  Further, that the defendants intentionally targeted opinion leaders in the medical community with financial incentives and misleading information in an effort to have the drug placed into treatment guidelines, model state treatment programs, formularies, Texas Vendor Drug Programs, and the Texas Medicaid preferred drug lists.

Attorneys for the State of Texas and Medicaid Marketing Fraud Whistleblower argued that they had reviewed millions of documents and could prove that the large drug company intentionally pushed Risperdal as a safer alternative to the typical medications despite rulings from the Food and Drug Administration that these assertions were not supported by scientific research.  Further, that the defendants orchestrated a fraudulent marketing scheme to seed medical literature with misleading information and influence key medical decision makers to increase Risperdal in the Texas Medicaid Program as well as used this information to push their drug as the established treatment in state Medicaid programs throughout the United States as well as in the Federal Medicare program.

As a result of this Texas lawsuit, the drug maker, Johnson and Johnson, Inc., agreed to settle the Texas Medicaid fraud case for $158 million.  Johnson and Johnson, Inc. has also agreed to a settlement where the drug company will will pay more than $1 billion in civil and criminal penalties to the federal government and individual states to settle an investigation into the marketing practices of its anti-psychotic drug Risperdal.  Johnson and Johnson, Inc. has also been hit in Medicaid fraud cases in South Carolina and Louisiana and was ordered to pay more than $250 million each.

International Health Care Procurement Whistleblowers Are Receiving Large Rewards for Exposing Government Health Care Procurement Bribe Schemes & other Government Procurement Corruption by International Government Health Care Procurement Bribe Whistleblower Lawyer, International Health Care Procurement Contract Bribe Lawyer, & International Pharmaceutical Procurement Illegal Kickback Whistleblower Attorney Jason Coomer

International Procurement Whistleblowers Are Receiving Large Rewards for Exposing Government Health Care Procurement Bribe Schemes and other Government Procurement Corruption by International Government Health Care Procurement Bribe Whistleblower Lawyer, International Pharmaceutical Procurement Contract Bribe Lawyer, and International Health Care Procurement Illegal Kickback Whistleblower Attorney Jason S. Coomer

Worldwide government purchasing or government procurement is estimated to be over $10 Trillion each year.  Of this large amount of government purchasing, it is estimated that as much as 20% may be through illegal bribes, kickbacks, and other illicit payments.  Government procurement spending includes military spending; public works projects; public health care (pharmaceuticals, medical equipment, & hospitals); ports, transportation, & roads; mining and oil extraction; power grid and stations; education; law enforcement; and sanitation services.  Because of the vast amount of money spent by governments on government procurement, there are many different types of government procurement illegal bribery schemes, illegal kickback schemes, and other illicit payment schemes that have been created to steal money from the public at the expense of a country's citizens.

Chinese Health-Care System Rife With Corruption Risks - Corruption Currents - WSJ

"Western companies seeking to find their way into China’s largely state-run health care system face heightened risks now that the Chinese government is planning to investigate drug-procurement and medical-device tendering. The tendering and procurement process is opaque and fragmented, giving companies more headaches when they try to enter the market, experts said."

"It becomes a bigger problem given news that China’s government, according to recent reports, is going to start inspecting hospitals’ invoices in a bid to curb commercial bribery and money laundering during the procurement process."

"The U.S. Justice Department has been in the middle of sweeping probes into both the pharmaceutical and medical-device industries. For example, orthopedic manufacturer Biomet Inc. agreed in March to pay the U.S. $22 million to settle FCPA charges that the company paid more than $1.5 million in direct and indirect payments to employees of state-owned health care providers in Argentina, Brazil and China to secure lucrative business with hospitals. The company didn’t enter a guilty plea, but accepted responsibility for the allegations laid out in court documents."

 International Health Care Procurement Whistleblowers Are Needed to Expose Government Health Care Procurement Bribe Schemes and other Government Procurement Corruption by International Government Medicine Procurement Bribe Whistleblower Lawyer, International Drug Procurement Contract Bribe Lawyer, and International Health Care Procurement Illegal Kickback Whistleblower Attorney Jason S. Coomer

Every year over $4.1 trillion (US dollars) is spent worldwide on health services including approximately $850 billion (US dollars) that is spent in the pharmaceutical market on drugs and medications.  In 2011, it is estimated that global pharmaceutical sales are expected to grow by 5% to 7% to around $880 billion.  This growth in sales is led by the 17 so-called "pharmerging countries," which include China, Brazil, Russia, India, Venezuela, Poland and the Ukraine.  These "pharmerging countries", are forecast to see their pharmaceutical spending grow at a 15% to 17% rate in 2011, to between $170 billion and $180 billion overall.

Eight pharmerging countries are amongst the top 20 world pharmaceutical markets, and China is one of the “top three” or will be in the near future.  A few high-profile pharmaceutical companies have been successful in gaining a foothold in these pharmering countries.  These footholds include Abbott’s acquisition of Piramal Healthcare in India — a deal that could potentially make the US giant the top player in this country.  Bayer's and Novartis' investments in China including Novartis'  commitment to invest $1 billion USD in R&D in China and its $125 million USD investment to buy 85 percent stake in a privately held vaccine company.  Pfizer has made inroads into the Russian health care system with a discount-card system in Russia  Sanofi Aventis has purchased Medley, Brazil’s third-largest pharmaceutical company.  GSK and Lilly have also announced anticipated doubling their revenue in emerging markets by 2015.

International Health Care Whistleblowers Are Exposing Government Health Care Procurement Bribe Schemes and other Government Procurement Corruption by International Government Health Care Procurement Bribe Whistleblower Lawyer, International Pharmaceutical Procurement Contract Bribe Lawyer, and International Health Care Procurement Illegal Kickback Whistleblower Attorney Jason S. Coomer

International Whistleblowers along the pharmaceutical supply chain and other health care professionals are being offered large potential rewards to blow the whistle on adulterated pharmaceutical ingredients, adulterated medicine, adulterated drugs, contaminated medical supplies, and defective medical devices.  These whistleblower rewards can come from SEC Whistleblower Reward Lawsuits and traditional Qui Tam False Claims Act Whistleblower Reward Lawsuits.  For more information on these potential whistleblower rewards, feel free to go to the following web pages: Government Contractor Procurement Fraud Lawsuits and International Government Procurement Bribe Whistleblower Rewards, International Procurement Bribe Whistleblower Lawsuits.

Securities and Exchange Commission Whistleblower Reward Law Designed to Expose Financial Fraud and Investment Fraud

Matthew H. Kluger and Garrett D. Bauer

Securities and Exchange Commission v. Matthew H. Kluger and Garrett D. Bauer, Case No. 11-cv-1936 (D.N.J. April 6, 2011) (KSH-PS); Securities and Exchange Commission v. Kenneth T. Robinson, Case No. 12-cv-2438 (D.N.J. April 25, 2011) (KSH-PS)

ATTORNEY, WALL STREET TRADER, AND MIDDLEMAN SETTLE SEC CHARGES IN $32 MILLION INSIDER TRADING CASE

Washington, D.C., April 25, 2012 – The Securities and Exchange Commission today announced a settlement in a $32 million insider trading case filed by the agency last year against a corporate attorney and a Wall Street trader.

The SEC alleged that the insider trading occurred in advance of at least 11 merger and acquisition announcements involving clients of the law firm where the attorney – Matthew H. Kluger – worked. He and the trader – Garrett D. Bauer – were linked through a mutual friend now identified as Kenneth T. Robinson, who acted as a middleman to facilitate the illegal tips and trades. Kluger and Bauer used public telephones and prepaid disposable mobile phones to communicate with Robinson in an effort to avoid detection. Robinson, now also charged, cooperated in the SEC’s investigation.
Bauer, Kluger, and Robinson each agreed to give up their ill-gotten gains plus interest in order to settle the SEC’s charges. Those amounts under the terms of their consent agreements are approximately $31.6 million for Bauer, $516,000 for Kluger, and $845,000 for Robinson.

Securities and Exchange Commission Whistleblower Reward Law Designed to Expose Financial Fraud and Investment Fraud

 Two relatively new whistleblower recovery laws are section 21F of the Securities Exchange Act (SEC Whistleblower Bounty Actions), and section 23 of the Commodity Exchange Act (CFTC Whisteblower Bounty Actions).    These laws were passed in the wake of Financial Market Melt Down in 2008 and in response to massive fraud in the financial markets.  These whistleblower recovery laws are designed to encourage people with specialized knowledge of significant investment fraud, securities fraud, SEC violations, commodity futures fraud, violations of the foreign corrupt practices act, and other financial fraud.  These whistleblower reward laws were designed to protect whistleblowers that step up and blow the whistle on financial fraud.

International Theft of Trade Secrets, International Patent Infringement, and International Intellectual Property Rights Infringement are on the Rise by International Patent Infringement Government Procurement Whistleblower Reward Lawyer, International Trade Secret Theft Procurement Whistleblower Lawyer, and International Patent Infringement Supply Chain Import Business Litigation Lawyer Jason S. Coomer

International Theft of Trade Secrets, International Patent Infringement, and International Intellectual Property Rights Infringement are on the Rise by International Patent Infringement Government Procurement Whistleblower Reward Lawyer, International Trade Secret Theft Procurement Whistleblower Lawyer, and International Patent Infringement Supply Chain Import Business Litigation Lawyer Jason S. Coomer

International theft of trade secrets and international intellectual property right infringement are on the rise as China, Mexico, Russia, and other emerging countries are seeking to improve their technology to move up the manufacturing value chain.  With fierce competition from countries such as Vietnam, Cambodia and Bangladesh attempting to undercut China's manufacturing of labor-intensive goods as well as higher end supply chain manufacturing competition from other emerging countries being placed on China, Russia, and Mexico; the pressure to obtain high end trade secrets and intellectual property has led to corporate espionage and theft of valuable trade secrets and intellectual property.  These products when used in other products can come through the supply chain and be the basis for patent infringement lawsuits, whistleblower reward lawsuits, and other types of lawsuits.

International Patent Infringement Government Procurement Reward Lawsuits, International Trade Secret Theft Government Procurement Whistleblower Reward Lawsuits, International Supply Chain Procurement Fraud Whistleblower Lawsuits, International Patent Infringement Qui Tam Lawsuits, and International Business Litigation Lawsuits

International theft of trade secret lawsuits, international patent infringement lawsuits, international intellectual property right infringement lawsuits, and other international business litigation lawsuits can be complicated legal matters requiring an experienced legal team to work across jurisdictions and work with different government entities.   These cases can become procurement fraud whistleblower reward lawsuits when internationally produced products reenter the United States and are sold to the U.S. Government or another governmental entity.

---

Establish U.S. Government-Wide Working Group to Prevent U.S. Government Purchase of Counterfeit Products
The 2011 IPEC Annual Report on Intellectual Property Enforcement

As the purchaser of over $500 billion in goods and services per year, the U S Government must ensure that it does not purchase counterfeit goods, secure its supply chain, and take the necessary steps to combat the evolving tactics of counterfeiters The Joint Strategic Plan established a government-wide working group to prevent the purchase and use of counterfeit products Over the last year, the IPEC convened an interagency group consisting of subject matter experts to develop an anti-counterfeiting framework that is flexible enough to accommodate the wide variety of missions across the government and their different systems of procurement The Office of Federal Procurement Policy (OFPP), Department of Defense (DOD), DOJ, and NASA have assumed leadership roles within the working group based on their vast expertise with U S Government procurement and anti-counterfeiting practices Other members include the DOC, Department of Energy, HHS, DHS, and Department of Transportation, the Environmental Protection Agency, the Missile Defense Agency, the General Services Administration, the Small Business Administration, the Nuclear Regulatory Commission, and the National Reconnaissance Office The main focus of this interagency working group is to ensure that the U S Government has the necessary tools to ensure that it does not purchase or use counterfeit products The working group is examining legislative authority, regulations, procurement policy and guidance, industry studies and reports, and international anti-counterfeiting standards in order to identify areas where risk to the security of U S Government supply chain from counterfeit parts can be reduced The working group developed six objectives to focus the group’s efforts to identify legislative, regulatory, or policy gaps and propose solutions to fill those gaps The six objectives are:

• Counterfeit Risk Assessment
• Supplier Requirements
• Traceability
• Testing and Evaluation of Goods
• Counterfeit Training and Outreach
• Enforcement Remedies

The group is developing a government-wide strategy using tools that are already at the U S Government’s disposal and creating new tools to combat the purchase or use of counterfeit goods by the U S Government The strategy will focus on reducing the risk of counterfeit items entering the supply chain, dealing efficiently with any suspected counterfeit items that do enter the supply chain, and strengthening remedies against those who provide counterfeit items to the U S Government.

International Patent Infringement Government Procurement Reward Lawsuits, International Trade Secret Theft Government Procurement Whistleblower Reward Lawsuits, International Supply Chain Procurement Fraud Whistleblower Lawsuits, International Patent Infringement Qui Tam Lawsuits, and International Business Litigation Lawsuits

For more information on International Patent Infringement Government Procurement Reward Lawsuits, International Trade Secret Theft Government Procurement Whistleblower Reward Lawsuits, International Supply Chain Procurement Fraud Whistleblower Lawsuits, International Patent Infringement Qui Tam Lawsuits, please click on the following link: International Patent Infringement Government Procurement Reward Lawsuit, International Trade Secret Theft Government Procurement Whistleblower Reward Lawsuit, International Supply Chain Procurement Fraud Whistleblower Lawsuit, and International Patent Infringement Qui Tam Lawsuit Information

International theft of trade secret lawsuits,

International Pharmaceutical Supply Chains Include Active Pharmaceutical Ingredient (API) Manufacturers, Pharmaceutical Intermediate Manufacturers, and Pharmaceutical Excipient Manufacturers All of Which Can Cause Adulterated and Dangerous Pharmaceuticals if Pharmaceutical Supply Chain Fraud Occurs by International Adulterated Drug Whistleblower Reward Lawyer Jason Coomer

International Pharmaceutical Supply Chains Include Active Pharmaceutical Ingredient (API) Manufacturers, Pharmaceutical Intermediate Manufacturers, and Pharmaceutical Excipient Manufacturers All of Which Can Cause Adulterated and Dangerous Pharmaceuticals if Pharmaceutical Supply Chain Fraud Occurs by International Pharmaceutical Supply Chain Fraud Whistleblower Reward Lawyer, International Adulterated Drug Whistleblower Lawyer, and International Pharmaceutical Executive Whistleblower Reward Lawyer Jason S. Coomer

Pharmaceutical suppliers of raw materials to the pharmaceutical industry include suppliers of active pharmaceutical ingredients (APIs), intermediates, and excipients.   It is the United States Food and Drug Administration's expectation that current good manufacturing practices (CGMP) be used for the manufacturing, processing, packing, or holding (i.e., storage) of active pharmaceutical ingredients (APIs), intermediates, and excipients.  Further, the FDA recommends that laboratory controls should include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures to ensure that raw materials, intermediates, APIs, and containers conform to established standards of quality and purity.

Traditional West European and North American API Manufactures have been Replaced by Indian API Manufacturers and Chine API Manufacturers

The active pharmaceutical ingredient (API) market is very competitive with many producers with many API manufacturers specializing and targeting their manufacturing based on joint venture contracts, large pharmaceutical company demand, governmental procurement contracts, regional resources and availability of supplies, and other logistical and profit driven factors. Driven by profits and lower costs, API manufacturing has slowly been shifting from the historical leaders in Western countries to newer firms in India and China.  

The overall API market was valued at $101.08 billion in 2010, and is expected to grow at a CAGR of 7.9% from 2011 to 2016.  In 2005, the total world API market was $76B and growing at an average annual rate of 8.2%. The market share held by Indian API manufacturers in the global API merchant market (generic APIs and branded/innovator APIs) was 6.5% in 2005, 12.0% in 2010, and is expected to increase to 22.0% by 2015. India is expected to be the fastest growing API supplier during the next five years and will keep its position above China. 

The market share held by Chinese companies in the global API merchant market (generic APIs and branded/innovative APIs) has risen from 14.2% in 2005 to 19% in 2010. Although China remains the largest API supplier on a global basis, growth rates from 2005–2010 of Chinese API suppliers were less than those of Indian suppliers. China’s share of the Western European generic API merchant market fell from 39.2% in 2005 to 35% in 2010. China’s share of the US generic API merchant market increased slightly from 11.5% to 12.9% in 2010. While Italy still remains the world market leader in APIs destined to sectors such as cardiovascular or the central nervous system, China leads in anti-infective APIs.

As a generalization, Chinese firms have tended to focus on the earlier raw materials stage whereas Indian firms have tended to focus more on the final API manufacturing stage. In many cases, a Chinese firm will make the raw material for a pharmaceutical product and then sell it to an Indian firm who will then convert the raw material into an API. Then, either the same firm, another Indian firm, a global Multinational Corporation (MNC) or a final formulator in a developing country will convert the API into a final formulation product ready for the market. However, the situation is rapidly evolving as both China and India gain new manufacturing skills. Not surprisingly, while many Western API firms have been winding down and/or consolidating their manufacturing capacity, many firms in India and China have been increasing capacity to meet the growing demand.

Traditional West European and North American Excipient Manufacturers have been Replaced by Indian Excipient Manufacturers and Chine Exipient Manufacturers

Pharmaceutical excipients play an important role in pharmaceutical formulations by adding functionality or by facilitating the processing of a drug product.  Recent trends in the pharmaceutical excipient manufacturer industry include: geographic expansion and select investment in emerging markets.  The global market for excipients totaled $4.9 billion in 2011. That value is projected to reach more than $6.7 billion in 2016 after increasing at a five-year compound annual growth rate (CAGR) of 6.5%.   The global excipients market can be broken down by material type into three segments – organic, inorganic, and USP (U.S. pharmaceutical) water.   The segment made up of organic excipients held a value of nearly $4.6 billion in 2011, and is expected to grow at a CAGR of 6.6% to reach a value of nearly $6.3 billion in 2016. The segment made up of inorganic excipients, worth $268 million in 2011, should be worth $350 million in 2016, a CAGR of 5.5%. The USP water excipients segment totaled $92 million in 2011, and in 2016 that value should reach $114 million, a CAGR of 4.4%.

Increased globalization and strategies for securing the supply chain are important issues for excipient producers. The International Pharmaceutical Excipients Council (IPEC) expanded into China in July 2008 with the formation of IPEC–China.

Regulations for Pharmaceutical Ingredients and Raw Materials

Regulation for pharmaceutical ingredients and raw materials can be complicated and can change depending on where the pharmaceutical ingredients are coming from and where they are being sold.  As such, an international producer from China or India that manufactures an API or excipient that sells it to a final formulator in the United States can be subject to the regulatory authorities in China and the United States.  The API or excipient manufacturer should be required to produce the product to the quality standards enforced by the Chinese authorities as well as will be required to meet USFDA standards as well.

International Adulterated Drug Supply Chain Whistleblower Reward Lawyer, International Pharmaceutical Supply Chain Fraud Whistleblower Lawyer, Medical Device Supply Chain Illegal Kickback Lawyer, Medicine Supply Chain Whistleblower Reward Lawyer, Medicine Supply Chain Fraud Lawyer, and Pharmaceutical Supply Chain Foreign Corrupt Practices Act Lawyer

International Whistleblowers along the pharmaceutical supply chain and other health care professionals are being offered large potential rewards to blow the whistle on adulterated pharmaceutical ingredients, adulterated medicine, adulterated drugs, contaminated medical supplies, and defective medical devices.  These whistleblower rewards can come from SEC Whistleblower Reward Lawsuits and traditional Qui Tam False Claims Act Whistleblower Reward Lawsuits.  For more information on these potential whistleblower rewards, please feel free to go to the following web pages: Adulterated Drug Quality Assurance Supply Chain Whistleblower Reward Lawsuits, International Pharmaceutical Supply Chain Fraud Whistleblower Lawsuits, and Medicine Supply Chain Whistleblower Reward Lawsuits.

IRS Tax Fraud Confidential Whistleblower Reward Information by IRS Tax Fraud Illegal Offshore Account Whistleblower Lawyer Jason S. Coomer

IRS Illegal Offshore Account Tax Fraud Whistleblower Lawsuit, Corporate Tax Fraud Whistleblower Reward Lawsuit, IRS Illegal Offshore Account Tax Fraud Whistleblower Reward Lawsuit, Transfer Price Scheme Tax Fraud Whistleblower Lawsuit, & other IRS Whistleblower Reward Lawsuit Information by IRS Illegal Offshore Account Tax Fraud Lawyer and Transfer Payment Tax Fraud Whistleblower Reward Lawyer Jason S. Coomer

Illegal Offshore Account Tax Fraud and Transfer Payment Tax Fraud are two forms of corporate tax fraud that are committed by large multinational corporations. The IRS is offering rewards and protections for IRS whistleblowers and IRS informants that work through Illegal Offshore Account Tax Fraud Whistleblower Lawyers, Multinational Corporate Tax Fraud Whistleblower Lawyers, and Transfer Payment Tax Fraud Whistleblower Lawyers to identify tax fraud schemes that cost the United States Billions of dollars.

IRS Illegal Offshore Account Tax Fraud Lawyer, Corporate Tax Fraud Whistleblower Reward Lawyer, IRS Illegal Offshore Account Tax Fraud Whistleblower Reward Lawyer, IRS Transfer Price Scheme Tax Fraud Lawyer, and IRS Whistleblower Reward Lawyer

Transfer pricing schemes involve the overpricing of imports and/or the underpricing of exports between related companies in different countries for the purpose of transferring profits or revenue out of the United States in order to evade taxes. The profits and revenue end up in a country that has a lower corporate tax rate than the US.  These fraudulent pricing schemes can be used both for stock manipulation and corporate tax fraud.  For more information on Corporate Tax Fraud Whistleblower Actions, please go to the following: Tax Fraud Whistleblower Reward Lawsuit, IRS Tax Fraud Whistleblower Award Lawsuit, and Corporate Tax Fraud Lawsuit Information web page.

Illegal Offshore Account Tax Fraud Lawsuit, Corporate Tax Fraud Whistleblower Reward Lawsuit, IRS Illegal Offshore Account Tax Fraud Whistleblower Reward Lawsuit, Transfer Price Scheme Tax Fraud Lawsuit, IRS Whistleblower Reward Lawsuit, & IRS Whistleblower Payment for Detection of Fraud Lawsuit Information

In 2006, the Tax Relief and Health Care Act that was signed into law included a whistleblower reward amendment that created mandatory reward language to the IRS to create a mandatory economic incentive to encourage tax fraud whistleblowers to step forward to help the government detect large scale fraudulent schemes.  By offering large potential rewards for reporting multimillion tax fraud schemes, the IRS has received hundreds of tax fraud tips from tax fraud informants regarding taxpayer fraud and massive violations of the tax code costing taxpayers Billions of dollars.  Many of the tips already received include fraud schemes of hundreds of millions and tens of millions of dollars.  It is estimated that this programs will result in hundreds of billions of dollars or even Trillions of dollars in tax fraud being detected. 

The economic incentives in the Tax Whistleblower Reward Programs are designed to encourage insider tax fraud informants and tax fraud whistleblowers with knowledge and evidence of large tax violations and tax fraud schemes to step forward and report the massive tax fraud.  The IRS is hoping that there will be several tax fraud whistleblowers and tax fraud informants that will help them detect and collect on an estimated $3 Trillion in illegal offshore accounts as well as several other tax-avoidance schemes that have been perpetrated by billionaires and millionaires as well as large corporations.

Stock Manipulation Scheme Lawsuit, Corporate Accounting Fraud Lawsuit, Fraudulent Accounting Lawsuit, False Accounting Statement Lawsuit, SEC Whistleblower Incentive Program Lawsuit, & SEC Bounty Action Lawsuit Information by Texas Corporate Accounting Fraud Lawyer, Stock Manipulation Lawyer, & False Accounting Statement Lawyer Jason Coomer

Stock manipulations schemes, false accounting statements, and other types of corporate accounting fraud cost pension funds and investors hundreds of Billions of dollars.  These fraudulent business practices are the target of new SEC Bounty Action laws and rules that encourage whistleblowers to anonymously step up and blow the whistle through a Bounty Action Lawyer on illegal stock manipulation schemes, false accounting, accounting fraud, Ponzi schemes, and other SEC violations.  By working with a stock manipulation bounty action lawyer to expose stock manipulation schemes, false misleading information on a company's financial statements, false information on Securities and Exchange Commission (SEC) filings, insider trading; embezzlement by stockbrokers; and other securities fraud, a SEC whistleblower can receive a large financial reward.  

 

Illegal Offshore Account Tax Fraud Lawsuit, Corporate Tax Fraud Whistleblower Reward Lawsuit, IRS Illegal Offshore Account Tax Fraud Whistleblower Reward Lawsuit, Transfer Price Scheme Tax Fraud Lawsuit, & IRS Whistleblower Reward Lawsuit Information by Illegal Offshore Account Tax Fraud Lawyer and Transfer Payment Tax Fraud Whistleblower Reward Lawyer Jason S. Coomer

The Federal Government including the SEC and IRS have recently amended and strengthened whistleblower reward laws to encourage accountant whistleblowers, financial analyst whistleblowers, and other high end professional whistleblowers with evidence of Accounting Fraud, Tax Fraud, Stock Manipulation Fraud, and other Investment Fraud to step up and blow the whistle on these fraud schemes.  By working through a Accounting Fraud Whistleblower Lawyer, Tax Fraud Whistleblower Lawyer, Stock Manipulation Fraud Whistleblower Lawyer, or other SEC Investment Fraud Whistleblower Lawyer, these whistleblowers can protect their identity and obtain large economic rewards.

For more information on these Whistleblower Reward, Bounty Action, and Protection Laws, feel free to go to the following web pages: Corporate Tax Fraud Lawsuits & Tax Fraud Whistleblower Lawsuit Information, Employee Whistleblower Award & Recovery Lawsuit Information, Corporate Illegal Kickback & Contract Bribe Whistelblower Award Lawsuit Information, Foreign Corrupt Practices Act Lawyer and SEC Bounty Action Lawsuit Information,  Confidential Financial Analyst Whistleblower Reward Lawsuit Information, Stock Manipulation Scheme & Corporate Accounting Fraud Lawsuit Information, and Multinational Corporation Tax Fraud Web Page Illegal Offshore Account Whistleblower and Multinational Corporation Fraudulent Transfer Payment Bounty Lawsuit Information

Fueled by Economic Incentives Many States Are Enacting Strong Medicaid Fraud Whistleblower Reward Laws That Provide Rewards and Protection to Whistleblowers by Medicaid Fraud Whistleblower Lawyer Jason S. Coomer

New State Medicaid Whistleblower Reward Laws Allow Medicaid Fraud Whistleblower Lawyers, Medicaid Hospital Employee Whistleblower Reward Lawyers, Hospital Whistleblower Lawyers, and Hospital Medicaid Fraud Whistleblower Lawyers to Protect Hospital Employee Whistleblowers From Retaliation

New state whistleblower reward laws are expanding the ability of Medicaid fraud whistleblowers to collect large economic rewards to encourage health care providers to blow the whistle on health care fraud including illegal Medicaid retention of overpayments, Medicaid illegal kickback schemes, Medicaid upcoding practices, Medicaid double billing practices, Medicaid false coding practices, Medicaid unbundling, and other fraudulent Medicaid billing practices.

The 2009 Fraud Enforcement and Recovery Act (FERA) and many new state Medicaid fraud whistleblower laws are expanding Medicaid fraud whistleblower recovery laws and other Bounty Reward Actions to increase potential rewards for relators, expand potential liability for Medicaid fraud criminals and violators, and to increase protections to Medicaid fraud whistleblowers. These new laws are designed to help the Federal government and state governments identify, recoup, and crack down on Medicaid fraud, Medicare fraud, and other forms of health care fraud which is estimated to be over $100 Billion per year.

With Medicare and Medicaid costs continuing to grow and many government budgets being tight, it is essential that health care providers with knowledge of Medicaid fraud, Medicare fraud, or other health care fraud to step up and expose the health care fraud and systematic Medicaid fraud that is the fasting growing and most lucrative crimes in the United States.

In developing and strengthening Medicaid fraud whistleblower laws, governments are setting up increased whistleblower protections and economic incentives to encourage health care providers to blow the whistle on traditional qui tam health care fraud causes of action and are expanding the causes of action to include rewards to whistleblowers that expose retention of Medicaid overpayments. Many of these False Claims Act statutes and Medicaid Fraud statutes have also been expanded to include government contractor false claims, government grantee false claims, and other recipients of government money that submit false claims to obtain this money.

For more information on potential Medicaid fraud whistleblower recoveries and Medicaid fraud whistleblower protections, please feel free to go to the following web pages:  Medicaid Fraud Whistleblower Lawsuit and Medicaid Fraud Whistleblower Reward Lawsuit Information and Medicaid Fraud Whistleblower Lawyer and Medicaid Whistleblower Reward Lawyer.

If your health care company has people that are committing Medicaid fraud, it is important to contact a Medicaid fraud whistleblower reward lawyer, Medicaid illegal kickback whistleblower reward lawyer, Medicaid upcoding whistleblower reward lawyer, Medicaid protected whistleblower double billing lawyer, Medicaid false coding whistleblower reward lawyer, Medicaid unbundling fraud whistleblower lawyer, or other health care fraud whistleblower lawyer to maximize your ability to obtain a substantial whistleblower recovery, understand whistleblower protections from potential retaliation, and protect yourself from potential liability.